Brexpiprazole
Serotonin dopamine partial agonist atypical antipsychotic
Brexpiprazole
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. The most common side effects include akathisia (a constant urge to move) and weight gain. The most common side effects among people with agitation associated with dementia due to Alzheimer's disease include headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia). Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor to aripiprazole (Abilify). It was approved for medical use in the United States in July 2015. A generic version was approved in August 2022, but is not yet available for sale due to multiple remaining patents expiring through 2029. Brexpiprazole is the first treatment approved by the US Food and Drug Administration (FDA) for agitation associated with...
Read on Wikipedia · Image Jynto (more from this user), CC0
Open boosters, collect cards and trade them. Free to play.
Play for free